Mepolizumab in COPD With Eosinophilic Bronchitis: A Randomized Clinical Trial.

Trial Profile

Mepolizumab in COPD With Eosinophilic Bronchitis: A Randomized Clinical Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2017 Results published in the European Respiratory Journal
    • 07 Mar 2016 Primary endpoint has been met. (Eosinophil count (Decrease in sputum eosinophil percentage.)), as per an abstract presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top